Merck, Schering-Plough shares under pressure from Vytorian data by The Star-Ledger Continuous News Desk Monday March 31, 2008, 9:28 AM Shares of drugmakers Merck and Schering-Plough were poised to post sharp declines this morning after medical researchers again said the companies’ joint anti-cholesterol drug, Vytorin, failed to improve heart disease. The researchers’ findings, published on the Internet by the New England Journal of Medicine, urged a return to more established treatments for c

More: continued here